Assessing the quality of real-world evidence in retinal diseases
Real-world evidence is growing in importance as a source of information that can help support clinical decision-making when evaluated properly.
ProQR doses first patients in late-stage QR-421a trial for retinitis pigmentosa, Usher syndrome
The company anticipates that the Sirius and Celeste studies will further validate QR-421a’s ability to stabilize vision loss in people with USH2A mediated retinitis pigmentosa and Usher syndrome.
Large fluctuations in central subfield thickness in DME: predictor of worse VA?
The difference in visual acuities based on CST fluctuations in these patients with diabetic macular edema remained significant.
High-quality, repeatable imaging is the cornerstone of managing diabetic eye disease
SD-OCT is providing reproducible, high-quality, registered images to assess the treatment response in macular disease.
How kidney function may play a role in DME treatment response
Investigators say renal function could be used as a possible predictor for poor treatment response in certain patients with diabetic macular edema.
Novartis announces positive results from year two of the Phase III trial of Beovu in diabetic macular edema
Novartis has revealed the first interpretable results from year two (week 100) of the Phase III KESTREL study.
Durable therapies for diabetic macular edema amid COVID-19 pandemic
Patients’ reluctance to visit a clinic during the COVID-19 pandemic is pushing retina specialists to optimize therapy.
Spect receives series seed funding for eye disease screening solutions
The company's AI-enabled mobile telemedicine platform helps clinicians capture retinal images and screen for vision-threatening eye diseases, such as diabetic retinopathy, glaucoma and age-related macular degeneration.
Unity reveals data from Phase 1 SAD study of UBX1325
Unity Biotechnology announces improvement in visual acuity sustained through 24 weeks following single dose of UBX1325 in Phase 1 study of patients with advanced vascular eye disease.
Coronavirus induces macrophage-mediated cytokine storm in diabetic patients
A team of investigators from the University of Michigan may have unlocked a potential new recipe for counteracting the impact that COVID-19 has on patients with underlying disease processes such as type 2 diabetes.
Oxurion announces positive results from Part A of phase 2 study evaluating THR-149 for treatment of DME
The company will move the highest dose of THR-149 (0.13mg) into Part B of the study based on favorable safety profile and positive efficacy data.
Unity Biotechnology announces positive data from Phase 1 trial of UBX1325
Investigators found evidence of improvement in vision and retinal structure in patients with DME and AMD sustained through 12 weeks.
Intravitreal anti-VEGF drugs effective for DME with caveats
A literature review indicates that intravitreal administration of anti-VEGF drugs are effective for treating DME, but close attention should be paid to the potential for elevated IOP, cataract progression.
Risk factors for vision loss with untreated DME and good baseline BCVA
Study: Older age and eyes with severe nonproliferative diabetic retinopathy or proliferative diabetic retinopathy had a higher risk of a vision loss event.
DME trial results are positive for intravitreal integrin antagonist
Option has a broader biologic effect for patients.
2 Clarke Drive Cranbury, NJ 08512